Acromegaly, the most serious risk associated with GH therapy, is not a realistic concern with properly dosed sermorelin. The intact somatostatin feedback axis prevents GH from rising above physiologically appropriate levels at standard doses.
Sermorelin is well tolerated at therapeutic doses. Most patients complete a 6-month protocol without significant adverse effects. The side effect profile is predictably dose-related: the higher the dose, the more likely mild effects appear. This guide separates the common and expected effects from the uncommon ones that warrant stopping the protocol, and identifies the contraindications that disqualify sermorelin use entirely.
- Standard starting dose: 100 to 150 mcg subcutaneously at bedtime
- Inject within 30 minutes of sleep onset to align with the natural GH pulse
- Avoid food for at least 2 hours before injection
- Reconstituted sermorelin must be refrigerated and discarded after 20 to 30 days
- Use a 28 to 31 gauge, 4 to 8 mm needle at a 45-degree angle for subcutaneous delivery
Common Side Effects: Expected and Self-Limiting
Injection site reactions are the most frequently reported effect. These include transient redness, minor swelling, or a small amount of bruising at the injection site. They typically appear in the first 2 to 4 weeks and resolve as the patient develops consistent injection technique. Rotating the injection site between the left and right periumbilical abdomen or lateral thighs reduces frequency.
- Injection site redness or mild swelling: most common, usually resolves within 1 to 2 hours
- Mild flushing in the face or upper body: reported in the first few weeks, typically resolves
- Headache at initiation: reported in a minority of patients, usually dose-related
- Transient fatigue the day after injection: occasionally reported, often resolves within 2 weeks
Dose-Related Effects at Higher Doses
Effects in this category appear at doses above 250 to 300 mcg per day and typically resolve when the dose is reduced. They reflect mildly elevated GH or IGF-1 activity rather than a toxic response.
- Mild water retention in hands, ankles, or periorbital area: typically resolves with dose reduction
- Joint stiffness or aching, most common in hands and wrists: resolves with dose reduction
- Carpal tunnel-like symptoms, tingling or numbness in hands: reduce dose, contact your provider
- Increased appetite: reported by some patients, correlates with elevated IGF-1
If you experience joint stiffness, water retention, or carpal tunnel-like symptoms, reduce your dose by 50 mcg and retest IGF-1 in 6 weeks. Do not stop the protocol entirely unless symptoms are severe or do not resolve after a dose reduction.
Uncommon Side Effects That Warrant Provider Contact
- Significant edema (visible swelling in the extremities): contact your provider same day
- Vision changes: rare, but blurred vision can indicate intracranial pressure changes
- Persistent headache beyond the first month: may indicate increased intracranial pressure
- Injection site infection with warmth, spreading redness, or pus: requires antibiotic treatment
- Severe nausea or vomiting: not a typical sermorelin effect; evaluate for other causes
Why Acromegaly Is Not a Relevant Risk at Standard Doses
Acromegaly, the condition caused by chronic GH excess, requires years of sustained supraphysiologic GH levels to develop. It is a documented risk of synthetic HGH at high doses. With sermorelin, the somatostatin feedback axis remains active. The pituitary self-regulates: when GH rises, somatostatin is released to suppress further secretion. This feedback mechanism makes physiologic GH excess unlikely at standard therapeutic doses of 100 to 300 mcg per day.
The 90-day IGF-1 retest catches dose-related excess before clinical consequences develop. Patients who keep IGF-1 within the upper half of their age-adjusted reference range are not at meaningful risk.
Contraindications: Who Should Not Use Sermorelin
- Active malignancy: GH and IGF-1 promote cell growth and may accelerate tumor growth
- History of GH-dependent tumor: pituitary adenoma, craniopharyngioma, or other GH-secreting tumors
- Diabetic retinopathy: IGF-1 elevation can worsen retinal vessel disease
- Uncontrolled hypothyroidism: thyroid function must be optimized before GH axis treatment
- Pregnancy or breastfeeding: no safety data; contraindicated
- Active intracranial hypertension: GH can raise cerebrospinal fluid pressure
Bottom Line
The side effect profile of sermorelin at standard doses is mild and manageable. Injection site reactions in the first few weeks and minor dose-related water retention or joint stiffness at higher doses are the effects most patients encounter. Absolute contraindications, particularly active cancer, must be screened at intake. Any provider that does not ask about these conditions before prescribing is not applying the clinical standard of care.
Frequently Asked Questions
Can sermorelin cause cancer?
Sermorelin is contraindicated in patients with active malignancy. Growth hormone stimulates cell growth, which is why active cancer is an absolute contraindication to any GH-axis therapy. There is no evidence that sermorelin causes cancer in patients without active malignancy. However, patients with a personal or strong family history of hormone-sensitive cancers should discuss the risk-benefit analysis with an oncologist before starting.
Can sermorelin cause acromegaly?
Acromegaly requires chronically elevated GH over years, typically from a pituitary tumor. Sermorelin at standard doses (100 to 300 mcg/night) cannot cause acromegaly because the intact somatostatin feedback axis prevents GH from exceeding physiologic levels. Acromegaly is not a clinically relevant risk for adults on standard sermorelin protocols with normal pituitary function.
Does sermorelin cause water retention?
Water retention is not listed as a common adverse event in the FDA-approved Geref label [1]. Fluid retention (edema) is a documented adverse event of recombinant HGH (somatropin) at higher doses; this class effect may be a clinical consideration when GH activity is elevated. If water retention occurs on sermorelin, contact the prescribing physician to discuss dose adjustment.
What should I do if I have an injection site reaction?
Mild redness, minor swelling, or transient bruising at the injection site are common in the first 2 to 4 weeks and typically self-resolve within 1 to 2 hours. Rotating sites, using a clean alcohol swab before injecting, and ensuring the needle length is appropriate (4 to 8 mm for subcutaneous delivery) reduces frequency. A reaction that persists beyond 24 hours, spreads, or is associated with fever warrants contacting the prescribing provider.
Can sermorelin be taken alongside thyroid medication?
Yes. Hypothyroidism does not contraindicate sermorelin, but uncontrolled hypothyroidism reduces IGF-1 response by impairing the liver's ability to convert GH to IGF-1. Patients on levothyroxine or other thyroid medications should have their thyroid function confirmed as optimized before interpreting a flat IGF-1 response. Thyroid medication does not interact pharmacokinetically with sermorelin.
References
- Geref (Sermorelin Acetate) Prescribing Information RxList (Geref FDA Label), 2008. NDA 19-863. https://www.rxlist.com/sermorelin-acetate-drug.htm
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMID: 18046908. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
- Sermorelin (Injection Route) Side Effects, Precautions, and Proper Use Mayo Clinic Drugs & Supplements, 2026. https://www.mayoclinic.org/drugs-supplements/sermorelin-injection-route/description/drg-20065923
- Effect of Growth Hormone on Insulin Signaling Molecular and Cellular Endocrinology, 2020. PMC7606590. https://pmc.ncbi.nlm.nih.gov/articles/PMC7606590/
